Skip to main content

Table 1 Basic characteristics between 5-ARIs User and comparison groups with Bladder Cancer (n = 5214)

From: 5α-reductase inhibitors impact prognosis of urothelial carcinoma

 

5-ARIs User, n (%)

None User, n (%)

P-value

Case No.

474

4740

 

Variables

 Age (Mean ± SD)

76.47 (±7.90)

76.60 (±8.51)

0.733

Age category (n, %)

 < 65

42 (8.86)

466 (9.83)

 

 65–74

153 (32.28)

1387 (29.26)

 

 > 75

279 (58.86)

2887 (60.91)

 

 CCI score (Mean ± SD)

4.23 (±2.18)

4.22 (±2.22)

0.959

CCI score category

 0 ~ 3

220 (46.41)

2203 (46.48)

 

 4 ~ 7

202 (42.62)

2037 (42.97)

 

 8+

52 (10.97)

500 (10.55)

 

Comorbidity

 Hypertension

258 (54.43)

2546 (53.71)

0.765

 Hyperlipidemia

88 (18.57)

842 (17.76)

0.664

 Diabetes mellitus

114 (24.05)

1121 (23.65)

0.845

 Chronic Kidney Disease

36 (7.59)

378 (7.97)

0.771

  1. CCI Charlson Comorbidity Index